---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045952"
form_type: "8-K"
ticker: "INFU"
cik: "0001337013"
company_name: "InfuSystem Holdings, Inc"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:22:33.383696+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# InfuSystem reports record Q3 revenue of $35.3M, up 11% YoY; net income +162%

## Summary
- Net revenue $35.3M (+11% YoY); Patient Services $20.8M (+8%), Device Solutions $14.5M (+15%).
- Net income $1.8M (+162%), diluted EPS $0.08; Adj EBITDA $7.9M (+27%), margin 22.3%.
- Operating cash flow YTD $12.5M (+91%); liquidity $46.9M as of Sept 30, 2024.
- Reaffirms FY2024 guidance: high-single-digit revenue growth, Adj EBITDA margin high-teens.
- New partnerships: Smith+Nephew for NPWT and exclusive Chemo Mouthpiece deal with Sanara MedTech.

## SEC filing metadata
- accession: 0001628280-24-045952
- form_type: 8-K
- ticker: INFU
- cik: 0001337013
- company_name: InfuSystem Holdings, Inc
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1337013/000162828024045952/0001628280-24-045952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1337013/000162828024045952/infu-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045952
- JSON: https://secwatch.observer/filing/0001628280-24-045952.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.